Logo

BCTXW

BriaCell Therapeutics Corp.

BCTXW

BriaCell Therapeutics Corp. • NASDAQ
$0.04 ▼ -9.05% (-0.00)
Market Cap $258826
52w High $0.06
52w Low $0.04
Dividend Yield 0%
P/E 0
Volume 3.73K
Outstanding Shares 6.78M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q4-2025 $0 $8.555M ▲ $-8.025M ▼ 0% $-4.26 ▲ $18.536M ▲
Q3-2025 $0 $6.328M ▼ $-6.127M ▲ 0% $-1.64K ▼ $-6.161M ▲
Q2-2025 $0 $7.169M ▲ $-6.291M ▼ 0% $-0.35 ▼ $-7.143M ▼
Q1-2025 $0 $5.153M ▼ $-5.802M ▼ 0% $-0.32 ▼ $-5.126M ▲
Q4-2024 $0 $5.768M $-1.214M 0% $-0.067 $-5.696M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q4-2025 $17.866M ▲ $21.65M ▲ $4.316M ▼ $17.334M ▲
Q3-2025 $12.46M ▲ $17.002M ▲ $5.061M ▼ $12.415M ▲
Q2-2025 $5.014M ▼ $9.364M ▼ $6.137M ▼ $3.603M ▼
Q1-2025 $5.792M ▲ $10.414M ▲ $6.701M ▼ $4.043M ▲
Q4-2024 $862.089K $5.872M $8.557M $-2.382M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q4-2025 $-8.164M ▼ $-8.132M ▼ $-7.391M ▼ $13.557M ▼ $-1.966M ▼ $-8.132M ▼
Q3-2025 $-6.225M ▲ $-7.163M ▼ $-105K ▼ $14.714M ▲ $7.447M ▲ $-7.163M ▼
Q2-2025 $-6.338M ▼ $-5.92M ▲ $-75K $5.217M ▼ $-778.611K ▼ $-5.92M ▲
Q1-2025 $-5.829M ▼ $-6.955M ▼ $-75K ▲ $11.96M ▲ $4.93M ▲ $-6.955M ▼
Q4-2024 $-1.249M $-4.036M $-456.801K $4.419M $-73.605K $-4.036M

Five-Year Company Overview

Income Statement

Income Statement BriaCell is still fully in the development stage, with no product sales so far and only ongoing research and corporate expenses. The company has reported steady operating and net losses year after year, reflecting the cost of running clinical trials and maintaining a small biotech platform without any offsetting revenue. Recent years show that losses have generally grown as the company ramps up its programs, which is typical for a clinical‑stage biotech but also increases financial pressure. Profitability is not in sight until and unless one of its drug candidates is approved and commercialized.

Balance Sheet

Balance Sheet The balance sheet is very light, with only a small base of assets and almost all of that in cash or cash‑like items. There is effectively no financial debt, which reduces interest burden but also highlights that the company relies mostly on equity financing. Shareholders’ equity has thinned out over time, suggesting repeated use of cash without a matching buildup of tangible assets or revenue. Overall, the company appears financially fragile and highly dependent on future capital raises or partnership funding to continue its clinical work.

Cash Flow

Cash Flow Cash is flowing out consistently to fund operations, mainly research, clinical trials, and overhead, with no inflows from product sales yet. Operating cash burn has been steady over the years, and there is essentially no spending on physical assets, which fits a lean, research‑focused biotech model. Given the small cash balance relative to the ongoing burn, the company’s runway appears limited and likely requires periodic new financing. The story here is a classic early‑stage biotech cash profile: modest but persistent outflows, no self‑funding, and dependence on external capital.

Competitive Edge

Competitive Edge BriaCell is competing in one of the most crowded and well‑funded areas of healthcare: cancer immunotherapy. Its edge lies in a distinctive “off‑the‑shelf but personalized” cell therapy approach that tries to combine the power of tailored treatments with the practicality and cost benefits of pre‑made products. The fast‑track status for its lead breast cancer program and encouraging early data in difficult‑to‑treat patients give it some scientific and regulatory credibility. However, the company is very small compared with large oncology players, has no approved drugs yet, and faces intense competition from multiple other immunotherapy platforms, so its position is promising but far from secure.

Innovation and R&D

Innovation and R&D Innovation is the clear strength of BriaCell’s story. The lead therapy, Bria‑IMT, and the broader Bria‑OTS platform are built around HLA‑matched, whole‑cell immunotherapy designed to be both scalable and personalized, which is a differentiated angle in oncology. The company is pushing this platform into a pivotal Phase 3 trial in metastatic breast cancer and testing variations across several other solid tumors using a bucket‑trial design, which can speed learning across indications. Collaborations with institutions like the U.S. National Cancer Institute and validation of its mechanism of action in peer‑reviewed journals further support the scientific foundation. At the same time, every asset is still in the clinical stage, so success ultimately depends on future trial results that are inherently uncertain and high risk.

Summary

BriaCell is a classic high‑risk, high‑uncertainty clinical‑stage biotech: no revenues yet, ongoing losses, and a very small capital base, but with a novel and ambitious immunotherapy platform. The company’s financials indicate limited resources and a need for ongoing external funding to sustain its trials. On the strategic side, its “off‑the‑shelf personalized” cancer immunotherapy concept, fast‑track designation, and expanding pipeline across multiple tumor types give it meaningful scientific and clinical upside if trials go well. Overall, the company’s future hinges on two things: the strength of upcoming clinical data—especially from the Phase 3 breast cancer program—and its ability to secure enough capital or partnerships to reach and potentially commercialize those milestones.